Please fill out the pre-assessment below before the session begins.

Please enable JavaScript in your browser to complete this form.

1. NGS results are important to predict prognosis of patients with MDS in all settings except: *

2. Luspatercept is approved in the USA for certain subsets of patients with lower risk MDS. What statement is correct?

A. Luspatercept is approved for patients with CCUS.
B. Luspatercept shows clinical activity only in SF3B1 mutated disease.
C. Luspatercept has been shown to sporadically improve platelet counts.
D. Luspatercept was shown to be inferior to epoetin-alpha in transfusion dependent patients.

3. What is the mechanism of action of imetelstat?

Medical Learning Institute Inc
40946 US Highway 19N #602
Tarpon Springs, FL 34689
888.654.2631 (toll-free)
609.333.1693 (direct)

Scroll to Top